Article summary
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the suspension of marketing authorisations of roughly 100 generic medicines that were tested by Synchron Research Services, a contract research organisation (CRO) in Ahmedabad, India. The recommendation comes after 'flawed' data and 'irregularities' were identified from bioequivalence studies conducted by the CRO.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial